Insulin growth factor receptor type 1 antisense therapy (Imvax)

N/A

Report date: 2026/05/12 09:09:39

Base Information

Drug NameInsulin growth factor receptor type 1 antisense therapy (Imvax)

Drug Alias NameIGF-1R/AS ODNIGF-1R antisense therapyType 1 insulin growth factor receptor antisense therapyIGV-001

ClassificationVaccines > Application > Therapeutic vaccineSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisenseCell and gene therapy > Cell therapy > Source of cells > Tumor-derived

Mechanisms of ActionCD4-positive T-lymphocytes stimulantsCD8-positive T-Lymphocytes stimulantsInsulin-like growth factor I receptor antagonists

TargetsInsulin-like growth factor I receptor

Therapy Area/IndicationsGlioblastoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesThomas Jefferson University

China Registration ClassN/A

Develop Information

Active CompaniesImvax

Inactive CompaniesN/A

Active IndicationsGlioblastoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A